ArticleACS omega2020
Investigating the Performance of Carboxylate-Alumoxane Nanoparticles as a Novel Chemically Functionalized Inhibitor on Asphaltene Precipitation.
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 31 citations in OpenAlex.
- Research Progress in Nanoparticle Inhibitors for Crude Oil Asphaltene Deposition.Molecules (Basel, Switzerland) · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, researchers have attempted to find some practical approaches for asphaltene adsorption and the prevention or postponement of asphaltene precipitation. Among different techniques, nanotechnology has attracted the researchers' attention to overcome the formation damage resulting from the deposition of asphaltenes. In this study, the application of two types of carboxylate-alumoxane nanoparticles (functionalized boehmite by methoxyacetic acid (BMA) and functionalized pseudo-boehmite by methoxyacetic acid (PBMA)) for asphaltene adsorption and precipitation was investigated. First, the synthesis of two functionalized nanoparticles was performed via the sol-gel method. For the assessment of the adsorption efficiency and adsorption capacity of these nanoparticles toward asphaltene adsorption, the batch adsorption experiments applying ultraviolet-visible (UV-Vis) spectroscopy were performed. The Langmuir and Freundlich isotherms were studied to describe the interaction between asphaltene molecules and carboxylate-alumoxane nanoparticles. For determining the "onset" point of asphaltene precipitation, the indirect method, which was based on the difference in the optical property of various solutions containing different concentrations of asphaltene, was utilized by applying UV-Vis spectroscopy. The isotherm models indicate that the adsorption of asphaltene on the surface of nanoparticles is better fitted to the Freundlich isotherm model compared with the Langmuir model. In the presence of PBMA (0.1 wt %), the onset point was delayed around 26, 20, and 17% in the asphaltene concentrations of 1000, 3000, and 5000 ppm, respectively, in comparison with their reference synthetic oils. On the other hand, these postponements for BMA nanoparticles (0.1 wt %) were 17%, 9%, and insignificant for the asphaltene concentrations of 1000, 3000, and 5000 ppm, respectively. The results reveal that two functionalized nanoparticles tend to adsorb asphaltene molecules and have a positive impact on the postponement of asphaltene precipitation due to molecular interactions between the surface of carboxylate-alumoxane nanoparticles and asphaltene molecules. However, PBMA nanoparticles exhibited better performance on the asphaltene adsorption and postponement of asphaltene precipitation, which is related to its smaller size, as well as higher surface area, compared with BMA nanoparticles.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.